Revolution Medicines Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Good morning, everyone. Thank you to everyone who is here in the room on the first morning of the Jefferies London Healthcare Conference. My name is Faisal Khurshid, Senior Biotech Analyst at Jefferies. Really pleased to have with us today Dr. Mark Goldsmith at RevMed. Mark has warned me that a lot of the questions that I have prepared, he may or may not be able to answer, but I will certainly try. Mark, could you kick us off with just a brief introduction, and then we will get into some questions that you may or may not answer?
Thanks very much for having us here today. Revolution Medicines is a company focused intensively on RAS-addicted cancers, RAS being the most common oncogene in human cancers. We have developed a very deep pipeline of RAS-focused compounds, inhibitors, many of which are in the clinic now, many of which are showing great promise. The most prominent one, of course, is now called RASONQUE, a commercial-stage compound just approved by the FDA late this summer, and now pending elsewhere around the world. We are completely committed to trying to defeat these RAS-addicted cancers, and our current therapies are making a difference, and we will continue investing to try to do even better.
Got it. Awesome, Mark. You just reported your first quarter of sales. Actually, it was not even a quarter, it was five weeks of sales. Can you just kind of recap for us what you saw in those first few weeks of your first reporting period? There were a number of investor questions about how to think about this going forward, but before we get into that a little bit, can I just get your perspective?
Right. We reported on five weeks of sales. Of course, that is a very short period of time. We did report net sales of $198 million during that period. There are many contributors to that, and I think our commercialization folks talked about that a bit on the call. There were several different categories of patients who received prescriptions during that period of time. Some of those patients came off of our expanded access program and converted or transitioned over to commercial drug. It was a very healthy expanded access program, one of the fastest programs with great uptake. There were greater than 2,000 patients in that program, and many of those patients did transition over to commercial drug. That would be essentially a one-time contributor. Those patients transitioned over and will take commercial drug as long as it is beneficial to them.
A second category in that group were patients who had not participated in the expanded access program in the U.S. but were waiting for drug, and many of those patients were late stage. Some of those patients were even on hospice care, and once the drug was available, were given an opportunity to take something that was highly differentiated from the options that they had already used up. That too is probably a roughly one-time population as more and more patients of the third group come online, and those are patients with previously treated disease but who have not advanced to third or fourth line, so-called second-line patients. That's really the core population that we studied in the RASolute 302 trial. The results were quite distinctive with the substantial hazard ratios and overall survival, progression-free survival, breaking the one-year barrier. Very much attracting attention by those second-line patients.
That third group will really ultimately form the core of the stable population that will enter treatment with RASONQUE as those first two groups work their way through the system. That first five-week period is a complicated period. We didn't break down the details of who those patients were, largely because there aren't patterns that are easily recognizable at this point in time. There's just too much variability. As things begin to stabilize, we'll of course provide more information. As we get into a more stable growth pattern, we'll share that information.
Yeah, Mark, the reason why this was. Obviously, investors don't like uncertainty, so your inability to kind of be able to parse out these three separate groups was just like a matter of discussion. I guess on a forward-looking basis, once you guys report fourth-quarter earnings, I guess two questions with that, right? Do you expect to be able to pre-announce your fourth-quarter revenues in January? Then also, at that point in time, whether it's in January or in February with proper 10-K filing period, would you expect to be able to give some clarity on how to think about the kind of one-off groups compared to your sort of regular way of demand?
Yeah. Well, we don't like uncertainty either, and the uncertainty is actually baked into the data. It's not a question of whether we disclose the data, that the uncertainty would remain with them, and that's just the nature of a launch that has had such a steep trajectory but also had substantial complexity in it because of the expanded access program. I can't comment today on when we'll first disclose the fourth-quarter results. We know there's a lot of interest in having those results. We have interest in having those results, and we don't have them yet. But we'll see when it's possible to disclose that. I think it's fair to say that over time, we'll get more granular about the various things that you're asking about, but I can't commit today to whether that's in the next quarter or in two quarters.
I think what we're going to do is to try to see patterns in the data. When things look like they are stable enough that one can use it as substantive information to project the future, that's when we'll be able to share it.
Got it. Can you just speak a little bit about what you guys have done to ensure kind of seamless execution and commercial availability? Something that really stood out to me was on the earnings call, you used the word responsibility and delivery to refer to kind of the mission that's ahead to kind of get this to patients. Can you just talk about what you've done to be prepared and what investments you've made to make sure this gets to patients?
Yeah. For many years now, we've had the concept that we would start as a discovery company, we'd move on to development, then we'd move on to delivery. Now we're in that delivery chapter. I think with the results that we reported on RASolute 302, we do have a great responsibility to physicians and patients, and we take that very seriously throughout the company. We, of course, had no commercial capability as a company two or three years ago. We anticipated the success of RASONQUE, at least on some level, and began investing in building commercial capability. We managed to recruit a very high talent group of individuals from established entities, well-known entities, that joined us and really had a blank slate.
They anticipated the possibility that we'd have an important medicines on our hand, one or more, and set out to build the relationships across the country. We had our medical affairs organization out for really the last two years, building relationships with investigators and with community docs. We spent a lot of time understanding RASONQUE itself. We had patient-reported outcomes as part of the trial. Every trial does have patient-reported outcomes, but this was a relatively unique case in which the patient-reported outcomes were statistically nearly identical to those of the objective data, indicating that patients felt that their experience of the drug matched what we were seeing objectively. That's very important information for doctors to have to be able to share with patients. There's also a side effect profile associated with RASONQUE, and we knew that. We saw that emerge. We developed approaches to mitigate when those side effects occur, and even more importantly, to pre-treat to try to reduce the incidence or severity of those side effects.
We developed a very straightforward system for educating physicians about that, and that is working well, and it is part of the process of establishing that this drug should be used more broadly. We also set up the (ON)Path Patient Services Program at RevMed, which is a dedicated group of professionals who respond very quickly to inquiries by physicians or patients about a whole range of topics, but now they are very focused, obviously, on third-party coverage. They facilitate if a patient has trouble getting coverage, they can step in, help to fill out prior auths, take care of that sort of thing while we are in the exception period, since most payers do not yet have established RASONQUE in their pathways.
That just takes a while to do. It is just the mechanics of it. They are not resistant at all to patients receiving it, but the systems are not in place, so we do some handholding of that. Of course, we also provide patient assistance, and our objective is to make sure that every patient who needs access to RASONQUE receives it, regardless of their ability to pay.
Got it. Mark, can I just ask you to sort of double-click on the point around tolerability? You spoke to the exceptional efficacy and quality of life outcomes that you saw in the study. For a couple of reasons, there was a prominent media report, and also, I think part of it is that there is not much else to pick at. Investors have kind of really concerned themselves to some extent with the tolerability profile of RASONQUE. Can you speak about what exactly you are doing to kind of ease any friction in the real world and what kind of results and feedback you are getting from the treating physicians?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
